18F-fluciclovine PET CT

DRUG2 trials

Sponsors

Blue Earth Diagnostics

Conditions

Cancer of the ProstateProstate Cancer

Phase 3

Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer

CompletedNCT02578940

Blue Earth DiagnosticsCancer of the Prostate

Start: 2015-11-30End: 2018-06-22Updated: 2019-10-07

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

CompletedNCT02680041

Blue Earth DiagnosticsProstate Cancer

Start: 2016-06-01End: 2017-11-01Updated: 2019-01-28

Related Papers

Impact of <sup>18</sup>F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials.

2023-04-292 citations

Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for <sup>18</sup>F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease.

2020-11-0510 citations

<sup>18</sup>F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE.

2020-05-256 citations

Impact of 18F-fluciclovine PET on salvage radiotherapy plans for men with post-radical prostatectomy recurrence of prostate cancer.

Journal of Clinical Oncology2020-02-191 citations

Effect of <sup>18</sup>F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial.

2020-02-1442 citations

Identification of bone involvement in patients with prostate cancer recurrence using <sup>18</sup>F-fluciclovine PET/CT and impact on subsequent management.

Journal of Clinical Oncology2019-03-01

The FALCON trial: Impact of <sup>18</sup>F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer.

Journal of Clinical Oncology2018-02-205 citations